

# Index

## 1–10

15-LO, 252, 259

5-LO, 149, 150

## A

A20, 316, 319

A2B5, 175–179, 437, 438

ADAM, 29, 340, 368, 544, 549

Adenomatous polyposis coli (APC) gene, 278, 281

Adherens junctions (AJs), 32

Adipokines, 143

Adracalin, 110

Adriamycin-resistance, 576

ADRP, 143–147, 154

Aldehyde dehydrogenase 1 (ALDH1), 533, 535, 547

Anaphase promoting complex/cyclosome (APC/C), 117, 593, 597

ANC-1, 256

Anergic, anergy, 199, 200

Annexin V staining, 584

Anti-apoptotic miRNAs, 503, 517

Antitumoral phenotype, 479, 488, 490

API (activator protein 1), 199, 278

API and TCF DNA-binding sites, 288

Apoptosis, 5, 102, 114, 115, 167, 168, 180, 181, 184, 205–209, 211–221, 223–229, 251, 259, 260, 266, 268, 359, 365, 366–373, 376, 377, 503, 506–521, 573–580, 584–587

Armandilo (ARM) repeat protein super-family, 279

AT-101, 230, 232

Ataxia teleangiectasia mutated (ATM)-protein, 221, 252, 264

ATP-binding cassette (ABC) transporter superfamily, 445

Autophagosome, 360, 361, 362, 366, 367, 371

Autophagy, 359–367, 369–378

AuTophagy-related (Atg) proteins, 360, 361, 366, 367, 371, 372, 373, 378, 380

## B

$\beta$ -catenin, 167, 182, 183, 260, 264, 273–279, 282, 285

$\beta$ -catenin/JNK, 277, 288

Baf250a, 471

Basal lamina, 15, 18, 34, 42, 400

Basic fibroblast growth factor (bFGF), 177, 178, 183, 184

Bcl2, 114, 115, 205–216, 220–224, 226, 232, 283, 301, 305, 310, 366, 368, 373–376, 506, 507, 513–516, 624, 626, 629, 632–636

BCL2-antagonist/killer protein (Bak), 206–214, 216, 219, 220, 221, 222, 225–227, 310, 366, 368, 506, 512, 514, 516, 622, 624, 631, 633

Bcl-2 associated death promoter, Bcl-2 antagonist of cell death (Bad), 207

BCL2-associated X protein (Bax), 206

Bcl-2 binding component 3 (bbc3), 215

BCL-2 family, 214, 517

Bcl2-interacting killer (Bik/Nbk), 208

Bcl-2 interacting mediator of cell death (Bim), 207–209, 211–216, 223–226, 228, 232, 309, 311, 314, 511, 515, 624, 632, 634

- Bcl-2 modifying factor (Bmf), 207, 208, 228, 229, 314, 506, 507, 517, 624
- Bcl-2 related ovarian death agonist (Bod), 214
- Beclin-1, 372–375
- BH3-interacting domain death agonist (Bid), 207, 208, 212, 214, 216–219, 223, 229, 309, 314, 366, 506, 507, 576, 577, 585, 587
- BH3-like motif, 375
- BH3 mimetics in anticancer therapy, 227–229, 232, 632
- BH3-only family, 225, 622, 624
- BH3-only protein, 205, 207, 214–216, 219, 220, 221, 222, 225–229, 233, 368, 373–375, 632, 634
- BH3 profiling, 229
- BH domains, 206
- BMI-1, 5, 6
- BMS-387032 (SNS-032), 630
- Bone marrow microenvironment in cancer dormancy, 561
- Bone-morphogenetic proteins (BMP), 277, 537
- Breast cancer, 44, 45, 71, 73, 78, 104, 167, 177, 179, 181, 254, 256, 258, 259–261, 267–269, 284, 289, 325, 339, 345, 351–353, 376, 379–381, 444, 446, 464, 470, 513, 514, 516, 535, 541, 543, 546, 550, 559–564, 614, 616, 617, 622, 624, 631, 634
- C**
- C75, 144, 153
- Ca<sup>2+</sup> channels, 107, 110, 117
- Ca<sup>2+</sup> microdomains, 102, 114
- Ca<sup>2+</sup>-NFAT pathway, 101
- Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channel, 94
- Ca<sup>2+</sup> sensing proteins, 94
- Ca<sup>2+</sup> waves, 105
- Cadherins, 7, 13, 22–26, 31, 33, 42, 543
- Calcineurin (CaN), 100, 116
- Calcium, 65, 67, 69, 70, 73, 76, 77, 80, 81, 82, 93, 102, 115
- Calcium channels, 65, 67, 70, 73–77, 78–83, 93, 101, 117, 119
- Calcium oscillations, 69, 102, 118
- Calcium oscillatory frequency, 102, 118
- Calmodulin (CaM), 68, 80, 97, 98
- Calreticulin, 110, 120
- Cancer associated stem cells, 401
- Cancer dormancy, 559, 560, 567
- Cancer evolution, 393, 395
- Cancer stem cell (CSC) hypothesis, 435, 463, 543
- Cancer stem cells (CSCs), 6, 168, 380, 403, 435, 533, 534
- Caspase 3, 286, 373, 506–508, 511, 512, 514, 516, 573, 575, 576
- Caspase activated DNase (CAD), 508
- Caspases, 219, 298, 309, 310, 318, 368, 371, 372, 506–508, 516, 623, 624, 626
- Catenin, 25, 26, 183, 277, 281
- Cathepsins, 221, 340, 369, 401, 482, 508
- Cavitation, 573–576, 578, 579, 587
- CBL-B, 195, 196, 201
- CCR7, 351
- CD24, 179, 380, 533, 535, 543, 545, 546, 550, 551
- CD28, 195, 198–201
- CD44, 178, 179, 284, 285, 376, 435, 531–533, 535, 539–544, 549, 550, 562, 563
- CD47, 533, 551
- CD133, 57, 178, 396, 400, 403–405, 416, 435–437, 440, 447, 448, 450, 465, 531, 533, 535–539, 541, 545, 548–550
- CD166, 533, 548, 549, 551
- Cdc2, 595, 596
- Cdc25, 594, 595
- CDC42, 510
- CDK-activating kinase (CAK), 592
- CDK in cancer treatment, 613, 635
- CDK inhibition, 613, 616, 618, 627, 635
- Cell adhesion molecules (CAMs), 13, 20, 40, 343, 424, 543, 551
- Cell cycle, 4, 65, 75, 82, 592
- Cell cycle block, cell cycle inhibition, 75
- Cell cycle inhibition, 619
- Cell junctions, 13, 15, 24, 41, 44, 45
- Cellular lipotoxicity, 157
- Cellular sensor pathways, 361
- Ceramidases, 174
- Ceramide glycosylation, 167, 171, 178, 183
- Ceramide synthesis, 171
- Checkpoint surveillance of cell cycle, 5
- Chemoattractant factors, 441
- Chemokines, 142, 339–341, 350, 397, 413, 445, 481, 484, 486, 488, 492, 493
- Chemoresistance, 215, 299, 305, 435, 443, 445–450, 542, 547, 549
- Chromatin remodeling, 251, 258, 268, 469–473
- Circulating tumour cells (CTCs), 395, 396, 397, 532
- Cisplatin-resistance, 576

- c-Jun, 215, 219, 227, 262, 263, 277, 278, 283, 286, 288–290, 297, 299, 315, 374
- Claudins, 35–37, 43
- c-Myc, 175, 177, 219, 258, 264, 267, 283, 288, 289, 511, 544, 545
- Collagen, 17–20, 27, 34, 407, 466, 470, 473, 482, 486, 492
- Communicating junctions, 37, 38
- Complex I, 307, 309
- Complex II (death-inducing signaling complex, DISC), 309–311, 314
- Connexons, 38
- COX, 149, 153, 155
- CpG islands, 469
- cSrc, 167, 180, 181, 183
- CX3CL1/fractalkine, 340
- CX3CR1 receptor, 351
- CXCR2, 481
- CXCR4, 481
- CXCR4/CXCR7 interactions, 344
- CXCL8, 348, 484, 486–488, 493, 494
- CXCL12-CXCR4, 561
- CXCL12 (SDF-1, stromal-derived factor), 341, 470
- CXCL14, 470
- CXCL16, 340
- CYC202, 617, 620, 629, 630, 633
- Cyclic ADP ribose, 81, 94, 112, 117, 265, 369, 508
- Cyclic AMP response element-binding (CREB), 118
- Cyclin, 4, 6, 80, 256, 285, 473, 591, 593–595, 597, 603, 604, 607, 612, 613, 619, 620
- Cyclin-dependent kinase (CDK, Cdk), 5, 66, 591–594, 609, 610
- Cytochrome C, 206, 226, 283, 310, 312, 368, 371, 372, 507–573, 575, 583–587, 624
- Cytochrome C-caspase 3 pathway, 573
- Cytokines, 9, 33, 66, 142, 216, 220, 262, 282, 296, 300, 303, 304, 312, 339, 340, 347, 362, 367, 395, 397, 408, 410, 415, 445, 465, 484, 486, 488–490, 492, 547, 560, 565, 629
- Cytoskeletal filaments, 7
- Cytoskeleton, 7, 8, 14, 19, 21–24, 26, 28–30, 32–35, 38, 39, 75, 106, 141, 143, 228, 277, 540, 542
- Cytosolic Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>cyt</sub>) transients, 66, 96, 101, 107, 111, 113, 117–120
- Cytosolic Ca<sup>2+</sup> signals, 93, 94, 108, 118
- Cytostatic factor (CSF), 116
- D**
- Damage-regulated modulator of autophagy (DRAM), 369
- Death-inducing signaling complex (DISC), 368–371, 623, 624
- Death receptors, 219, 220, 302, 306, 367–371, 421, 506, 516, 517, 623
- Delta receptors, 41
- Delta-24-RGD, 451
- Desmosomes, 15, 23, 24, 25, 27, 29, 31, 33–34
- Diacylglycerol (DAG), 66, 94, 110, 199, 344, 482
- Disintegrins, 27, 29, 340
- DNA methylation, 57, 218, 468–473
- E**
- E-cadherin, 8–10, 263, 264
- EGTA buffering, 79
- Eicosacell, 150
- Eicosanoid, 148–150, 153
- Embryonic carcinoma cells (EC cells), 534
- Embryonic rest hypothesis of cancer development, 55
- Embryonic stem cells (ESCs), 167, 168, 533
- Emerin, 110
- EMT, 8, 9, 263, 264, 393, 396, 538, 541, 542, 545
- Endonuclease G (EndoG), 508
- Endoplasmic reticulum, 65, 67, 94, 96, 110, 111, 169, 170, 214, 361, 362, 578, 580, 581, 583
- EpCAM, 535, 537, 541–545, 549, 550
- Eph/ephrin, 277
- Ephrin receptor (EphR), 41
- Epiblast, 51, 53–56, 60
- Epidermal growth factor (EGF), 6, 21, 43, 73, 103, 217, 258, 351, 400, 414, 417, 419, 436
- Epigenetic changes in imprinted genes, 56
- Epigenetic states, 463, 465, 468, 469, 470
- Epithelial–mesenchymal transition (EMT), 8, 179, 252, 263
- Extracellular matrix (ECM), 14, 15, 393, 398, 400, 401, 409, 410, 414, 422
- Extracellular signal-regulated kinase (ERK), 102, 103, 118, 119, 167, 180, 181, 215, 260
- F**
- Ferritin heavy chain (FHC), 316, 324
- Fibronectin, 18, 29

FLAP, 149  
 Flavopiridol (alvocidib), 616–625, 630  
 Focal adhesion, 32  
 Focal adhesion kinase (FAK), 32, 44, 46  
 Free radicals, reactive oxygen species (ROS),  
 217, 298, 299, 305, 311, 312, 316,  
 320–327, 363, 366, 378, 444, 445,  
 484, 485, 490, 491, 574

## G

G1 arrest, 68  
 Gadd45 $\beta$ , 315–318, 327  
 Ganglio-series glycosphingolipids (GSLs),  
 171–174, 178  
 Gap junctions, 37, 38  
 Gb3, 173–179, 183, 184  
 Gb5 (SSEA-3), 167  
 GD2, 167, 173, 176, 177, 179, 184  
 Germ line, 53, 54  
 GlcCer synthase (GCS), 170, 171, 177–179,  
 183  
 Glioblastoma (GBM), 177, 181, 182, 230,  
 345, 390, 392  
 Glioma stem cells (GSCs), 393, 435, 436–440,  
 449, 450, 451  
 Globo-series glycosphingolipids (GSLs), 167,  
 171, 172, 173, 177, 178, 183, 184  
 Glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ), 257,  
 260, 277, 278  
 Glycosaminoglycans (GAGs), 16, 17,  
 342, 485  
 Glycosphingolipids (GSLs), 167, 168, 178  
 GM1, 110, 176, 177, 184  
 G-protein-coupled receptor, G-protein-linked  
 receptor (GPCR), 67, 69, 96, 97,  
 99, 101–104, 287, 484, 533,  
 535, 537  
 GSK3- $\beta$  pathway, 252, 281, 260, 264, 278

## H

HBx, 261, 262  
 Hedgehog, 277, 405  
 Hemidesmosomes, 34  
 Heregulin (HRG), 252, 258  
 Histone deacetylase (HDAC), 113, 215,  
 228, 252, 256, 259, 260, 264,  
 268, 269  
 Histone modification, 468, 469, 470, 472, 473  
 Hrk (Dp5, Harakiri), 206, 208, 222, 223, 224,  
 225, 226  
 Htr2/Omi, 508

Hyaluronan-mediated motility receptor  
 (HMMR), 263  
 Hypoxia, 150, 224, 347, 360, 362, 379, 396,  
 406, 407, 410, 411, 442, 443, 466, 470,  
 472, 486, 493  
 Hypoxia inducible factors (HIFs), 252, 253,  
 260, 379, 442, 472

## I

Ig-like CAM, 30  
 I $\kappa$ B kinase (IKK), 298, 300, 301, 303,  
 306, 307, 310, 327  
 I $\kappa$ B kinase (IKK2), 98, 115  
 Inflammation, 9, 17, 30, 52, 56, 143, 148,  
 151, 152, 156, 249, 283, 297, 299,  
 300, 303, 311, 319, 327, 339, 344,  
 349, 360, 366, 394–396, 484,  
 494, 495  
 Inflammatory lipid mediators, 139, 150, 484,  
 486  
 Innate immune response, 320, 360, 477, 479,  
 480, 492  
 Inositol 1,4,5-trisphosphate (InsP3)IP3, 66, 94,  
 96, 110  
 Inositol-1,4,5-trisphosphate (InsP3) receptor  
 (IP3R), 81, 96, 110  
 Insonation, 574–579, 587  
 Insulin-like growth factor 2 (Igf2)-H19 locus,  
 53, 59, 109  
 Integrins, 20, 26–29, 44, 441, 481, 483, 485,  
 494  
 Intracellular Ca<sup>2+</sup> store, 7, 68, 94, 97,  
 101, 109, 115  
 Intrinsic apoptotic pathway, 205, 218, 517

## J

JARID1B, 467, 468  
 JNK MAPK cascade, 309  
 Jun-N-terminal kinase (JNK) cascade, 227,  
 228, 278

## L

Lamin B receptor, 110  
 Laminin, 18, 19, 27, 29, 34,  
 471, 482  
 Lgr5, 287, 535, 541, 547, 551  
 Lipid droplet (lipid body or adiposome),  
 139–144, 148–157  
 Lipid rafts, 80, 97, 173, 343  
 Lipopolysaccharide (LPS), 252, 262

**M**

Macroautophagy, 359, 360, 382, 386, 387, 389, 390

MAPK, 109, 118, 179, 183, 190, 200, 279, 280, 282, 295, 298, 299, 301, 303, 309, 312, 317, 322

Matrix metalloproteinase, 103, 278, 288, 317, 340, 350

Mergylation (of DNA), 480, 486

Mesenchymal stem cells (MSCs), 9, 392, 393, 403, 412, 416, 561, 568

Mesenchymal to epithelial transition (MET), 396

Metalloproteinase (MMP), 288, 350, 441, 464, 486

Metastasis-associated gene (MTA), 252, 253

Microautophagy, 359

Microna, 58, 215, 252, 262, 267, 397, 399, 439, 440, 468, 469, 515, 517, 521, 538, 542

Migration, 3, 7, 9, 10, 21, 29, 33, 66, 155, 199, 256, 259, 267, 277, 344, 401, 411, 413, 418, 439, 441, 473, 485, 494, 536, 546, 613, 636

miR-29, 509, 510, 517

miR-34, 507, 510, 511, 517, 565

miR-153, 509, 511

miRNA, 469, 472, 473, 471, 503–506, 509, 510, 512–521, 538, 562, 567

miRNA induced silencing complex (miRISC), 504, 505

Mitochondrial dysfunction, 156, 205, 226, 227, 369

Mitogen-activated protein kinases (MAPKs), 109, 200

Mn-SOD, 298, 316, 323, 326

MRP1, 444, 446–449

MSGb5 (SSEA-4), 661

mTOR, 144, 156, 361, 362, 366, 376, 378, 418, 419, 450

Multidrug resistance (MDR), 443, 444

Myeloid differentiation primary response gene 88 (MyD88), 252, 262

**N**

N1 neutrophils, 489, 491

N2 neutrophils, 490, 492, 493, 494

Nanosecond electric pulses, 573, 574, 580, 587

Nanosecond-pulsed electric fields (ns-PEF), 587, 585

Navitoclax (ABT-263), 233

Necrosis, 262, 297, 298, 300, 308, 359, 365–369, 381, 397, 415, 420, 488, 506, 578, 579, 587

Nestin+/CD133+ cancer cells, 406

Neuronal pathologies

Neuron-specific C, 591, 592, 609, 610

Neuroprotection, 591, 611, 613

Neurosphere culture, 436, 437

Neutrophils, 150, 151, 320, 371, 479, 480, 481, 483, 484–495

NFAT, 40, 81, 99, 100–103, 115, 116, 199, 200

NF- $\kappa$ B, 98, 99, 102, 113, 115, 116, 199, 200, 262, 297, 298, 299–307, 309, 311, 313–327, 362, 371, 378, 484, 604, 622, 626, 632, 634

Niche, 149, 178, 183, 289, 351, 392, 397, 402–410, 435, 440–443, 451, 452, 463–468, 559, 560

Nicotinic acid adenine dinucleotide phosphate (NAADP), 94, 112

Non capacitative calcium entry (NCCE)

Non EMT-CSC, 545

Non-steroidal anti-inflammatory drugs (NSAIDs), 153

Notch, 39, 41, 277, 402, 405, 406, 407, 514, 544

Notch receptors, 41

Noxa, 208, 211, 216, 223, 224, 232, 324, 377, 509, 624, 632

Nuclear Ca<sup>2+</sup> signals, signaling, 93, 94, 107–109, 113, 121

Nuclear envelope (NE), 69, 93, 105, 110, 226, 581, 582–584, 597

Nuclear pore complex (NPC), 106, 111

Nucleoplasmic reticulum, 106, 108–110, 113

Nucleosome remodeling, 251–253, 258

Nucleosome remodeling and histone deacetylation (NuRD), 251, 252, 253, 258

**O**

Obatoclax (GM15-070), 230, 232, 632

Ocludins, 13

Oct-4<sup>+</sup> cells, 56

Oncolytic viruses, 394, 414, 416, 451

ORAI, 69–75, 77, 80–82, 94–97, 99, 100, 102, 104, 107

**P**

p21, 260, 265, 285, 511–513, 575–577, 594, 598, 599, 614–616, 628, 632, 633

- p53, 115, 156, 208, 215–218, 221, 223, 224, 226, 227, 251, 253, 260, 262, 263, 265–269, 285, 369, 376, 377, 399, 508–513, 515, 519, 575–577, 585, 599, 607, 616, 625, 628, 629, 630
- p53 upregulated modulator of apoptosis (Puma), 208, 216
- p85 alpha, 510
- PAT, 145–147, 153
- Pathogen-associated molecular pattern (PAMP), 483
- Peripheral T cell tolerance, 195, 200
- Phosphatases, 25, 38, 199, 222, 322, 593
- Phosphatidylinositol 3'-OH kinase (PI3K), 508
- PI3K, 142, 143, 151, 360, 376, 399, 405, 449, 509
- Platelet-activating factor (PAF), 142, 484
- Pluripotency, 10, 57, 58, 167, 168, 174, 180, 182–184, 265, 463, 465, 541, 545, 546, 548, 551, 563, 565
- PolIII, 252, 261–264, 266
- PP2A, 97–99, 115, 178, 183, 280
- Primordial germ cells, 54, 59
- Pro-apoptotic drugs, 421
- Pro-apoptotic miRNAs, 510–512, 515
- Programmed cell death (PCD), 205, 225, 297–299, 365, 379, 470, 486, 503
- Proliferation, 5, 10, 20, 44, 53, 58, 66–75, 79, 82, 103, 152, 179, 180, 181–184, 263, 281–285, 303, 317, 344, 409, 466, 480, 487, 493, 510, 516, 542, 545, 595, 611, 613, 616, 635
- Promyelocytic leukemia (PML), 115
- Protein kinase B/Akt (PKB), 97–99, 115, 120
- Proteoglycan (PG), 17, 19, 39, 613
- Proteolytic cascade activation, 400, 401
- Proto-oncogenes, 5, 42
- Protumoral phenotype, 479, 488, 495
- Pulsed electric fields (PEF), 581–587
- R**
- Rad3-related protein (ATR), 252, 264, 265, 608, 629
- Reactive oxygen species (ROS), 217, 298, 305, 309, 311, 316, 320, 363, 367, 377, 444, 484, 488, 491, 578, 579
- Receptor tyrosine kinases (RTK), 34, 94, 96, 97, 98, 109, 399, 400, 514
- Recombinant antibodies, 417
- Regulatory RNAs, 503
- Ryanodine receptor (RyR), 102, 112
- S**
- S1P, 167, 168, 174, 180, 183
- S1P receptor (S1PR), 167
- Sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA), 112
- Selectins, 20–22, 30, 483, 485
- SERCA, 82, 107
- Slug, 9, 10, 218, 263, 464
- Smac/DIABLO, 310, 368, 507, 508, 624
- Small ubiquitin-related modifier (SUMO), 268
- Snail, 9, 10, 263, 464
- Sonochemotherapy, 575, 578
- Sonodynamic therapy, 575, 576
- Sphingolipids, 35, 167, 168, 173, 176, 182, 184
- Sphingosine-1-phosphate, 168, 169, 173, 179
- SSEA-1, 57, 437, 438
- Stem cells, 3–6, 44, 51–58, 102, 118, 167, 168, 176, 183, 217, 221, 265, 339, 364, 391, 396, 400, 405, 406, 407, 412, 422, 434, 438, 443, 449, 463–466, 534, 543, 546, 548, 560–568
- Store operated Ca<sup>2+</sup> entry (SOCE), 67, 72–82, 95–97, 99, 102, 117
- Stromal interaction molecule (STIM), 67, 75, 77, 94, 96, 98–104
- T**
- T cell activation, 40, 195, 197, 198, 201
- TCF4, 282, 288
- TCF/LEF family of transcription factors, 279, 289
- Tight junctions (TJs), 14, 35, 37, 44
- TNF-R associated factor, 305, 307
- Toll-like receptor (TLR), 17, 262, 302, 303, 362, 363, 480, 481
- Transdifferentiation, 404, 411, 546
- Transforming growth factor (TGF), 27, 183, 252, 264, 298, 304, 308, 350, 353, 464
- Transforming growth factor  $\beta$  (TGF- $\beta$ ), 180, 252, 298, 304, 308, 350, 353, 464
- Transient receptor potential canonical cationic channel (TRPC), 67
- Tregs, 201
- TRP channels, 72, 81
- TRPM channels, 81
- Tumor-associated macrophages (TAMs), 304, 349, 350
- Tumor-associated neutrophils, 479, 490, 491
- Tumor-infiltrating lymphocytes, 350
- Tumor-initiating cells (TICs), 380
- Tumor initiation, 42, 304, 349, 359, 376, 377, 438, 442, 463, 467, 473, 492, 493

Tumor microenvironment, 201, 339, 393, 467, 469, 470, 471, 491, 492  
Tumor necrosis factor (TNF)- $\alpha$ , 298  
Tumor necrosis factor (TNF) receptors, 297, 308  
Tumor necrosis factor (TNF) receptor superfamily, 367, 506  
Tumor progression, 359, 369, 378, 379, 392, 393, 395, 396, 437, 441, 442, 444, 470, 489, 492, 516  
Tumor suppressor genes, 5, 6, 42, 348, 376, 516  
Tumor vasculature, 347, 422, 441, 442, 452, 466  
Twist, 464, 542

**U**

Ubiquitination, 195, 307  
Ubiquitin ligases (E3 ligases, E3s), 195, 196–198, 213, 262, 277, 362, 622  
ULK1, 376  
Ultrasound, 573–575, 578, 579, 587  
Ultrasound induced apoptosis, 575

**V**

Vascular endothelial cell growth factor (VEGF), 16, 25, 27, 73, 255, 261, 348, 350, 397, 402, 407, 440, 442, 480, 489, 626  
Vascular endothelial growth factor receptor-2 (VEGF-R2), 16, 25  
Very small embryonic/epiblast-like stem cells (VSELs), 51, 53, 59  
Voltage-gated calcium channels, 40, 73, 78, 117–119

**W**

Wnt, 25, 181, 260, 277–282, 287–290, 406, 467, 537, 540, 541, 544, 545, 547, 548

**X**

XIAP, 298, 305, 316, 318, 511, 516, 624, 626, 629, 630, 632

**Z**

Zeb, 464